Loxo Oncology
develops and markets genomic medicines for the treatment of cancer... Read moreLoxo Oncology
develops and markets genomic medicines for the treatment of cancer... Read more
CEO
Jacob S. Van Naarden
News
Dec 26, 2023
Pharamceutical Technology
Loxo Oncology: LOXO-435 by Loxo Oncology for Solid Tumor: Likelihood of Approval
Oct 04, 2023
MarketScreener
Loxo Oncology: Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Jul 06, 2023
StreetInsider
Press Release: Loxo Oncology : New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
May 11, 2023
PR Newswire
Press Release: Loxo Oncology : Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
Dec 12, 2022
StreetInsider
Press Release: Loxo Oncology : Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting
Jun 02, 2022
BizWest
Loxo Oncology: New Loxo@Lilly facility brings oncology R&D to Louisville
Dec 13, 2021
BioSpace
Loxo Oncology: Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control Platform
Dec 13, 2021
Pharmabiz
Loxo Oncology: Loxo Oncology at Lilly announces updated data from phase 1/2 BRUIN trial of pirtobrutinib in patients with CLL, SLL & MCL
Dec 12, 2021
firstword pharma
Loxo Oncology: Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting
Oct 07, 2021
Markets Insider
Loxo Oncology: Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Loxo Oncology Competitors
1
2
3
4
5
6
7
8
9
10